We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

38 hedge funds and large institutions have $241M invested in ProQR Therapeutics in 2015 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more capital invested

Capital invested by funds: $167M → $241M (+$73.9M)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

9% more funds holding

Funds holding: 35 → 38 (+3)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
13
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$44.4M
2
Millennium Management
Millennium Management
New York
+$10.8M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$8.43M
4
Jennison Associates
Jennison Associates
New York
+$8.12M
5
JHIU
Janus Henderson Investors US
Colorado
+$7.58M

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$3.76M
2
FCMI
Foresite Capital Management II
California
-$3.75M
3
DM
Deerfield Management
New York
-$3.52M
4
SFM
Sphera Funds Management
Israel
-$2.82M
5
SM
Sabby Management
Florida
-$2.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$417K +$161K +7,779 +69%
CLM
27
ClearBridge LLC (Maryland)
Maryland
$381K – – –
PC
28
Polar Capital
United Kingdom
$360K -$47.6K -2,307 -12%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$346K +$326K +15,806 New
CSS
30
Cubist Systematic Strategies
Connecticut
$286K +$270K +13,064 New
SCM
31
Sterling Capital Management
North Carolina
$280K -$55.2K -2,672 -18%
Citadel Advisors
32
Citadel Advisors
Florida
$210K +$198K +9,597 New
ARTA
33
A.R.T. Advisors
New York
$205K +$194K +9,404 New
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$55K +$51.6K +2,500 New
UBS Group
35
UBS Group
Switzerland
$12K +$1.75K +85 +19%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$11K +$10.8K +524 New
TRCT
37
Tower Research Capital (TRC)
New York
$5K +$4.42K +214 New
HMS
38
Hanseatic Management Services
New Mexico
$1K +$640 +31 New
PC
39
PointState Capital
New York
– -$3.76M -173,500 Closed
FCMI
40
Foresite Capital Management II
California
– -$3.75M -173,067 Closed
SFM
41
Sphera Funds Management
Israel
– -$2.82M -130,000 Closed
PA
42
Perceptive Advisors
New York
– -$2.17M -100,000 Closed
WMSA
43
Weiss Multi-Strategy Advisers
New York
– -$1.72M -79,300 Closed
Alyeska Investment Group
44
Alyeska Investment Group
Illinois
– -$1.32M -61,115 Closed
BA
45
BlackRock Advisors
Delaware
– -$1.31M -60,600 Closed
Bank of America
46
Bank of America
North Carolina
– -$2K -100 Closed
1
2

PRQR Hedge Fund Activity: Q1 2015 in Review

38 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2015, worth a combined $241M — up 44% from $167M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new PRQR positions and 8 closed out — a net gain of 3 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $44.4M. The largest seller was PointState Capital, exiting entirely with an estimated $3.76M sold.

  • 38 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2015, up from 35 in Q4 2014.
  • Funds reported $241M of ProQR Therapeutics stock for Q1 2015, up 44% quarter-over-quarter.
  • 11 funds opened new ProQR Therapeutics positions in Q1 2015 and 8 closed out, a net change of +3 holders.
  • The largest ProQR Therapeutics buyer in Q1 2015 was Fidelity Investments, an estimated $44.4M added.
  • The largest ProQR Therapeutics seller in Q1 2015 was PointState Capital, an estimated $3.76M sold.

Based on aggregated 13F filings for Q1 2015.